What is the difference between Propranolol (beta-blocker) and Metoprolol (beta-1 selective blocker) in treating hyperthyroidism with palpitations?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Propranolol vs. Metoprolol for Hyperthyroidism with Palpitations

Propranolol is superior to metoprolol for treating hyperthyroidism with palpitations due to its non-selective beta-blocking properties that not only control heart rate but also inhibit peripheral conversion of T4 to T3. 1

Mechanism of Action Differences

  • Beta-receptor selectivity: Metoprolol is a beta-1 selective (cardioselective) adrenergic receptor blocker, primarily affecting cardiac tissue, while propranolol is non-selective, blocking both beta-1 and beta-2 receptors 2
  • Peripheral conversion effects: Propranolol inhibits the peripheral conversion of T4 to the more biologically active hormone T3, providing additional benefit in hyperthyroidism that metoprolol lacks 1, 3
  • Tremor control: Propranolol's non-selective properties make it more effective for controlling hyperthyroid tremor, which is mediated through beta-2 receptors 4

Clinical Efficacy in Hyperthyroidism

  • Heart rate control: Both propranolol and metoprolol effectively reduce heart rate in hyperthyroid patients, but propranolol produces a significantly greater reduction 3, 5
  • Thyroid hormone effects: Propranolol decreases serum T3 levels and increases reverse T3 (rT3), while metoprolol has minimal effect on thyroid hormone levels even at higher doses 3, 6
  • Symptom management: Propranolol is more effective at controlling multiple hyperthyroid symptoms including nervousness, palpitations, tachycardia, increased cardiac output, and tremor 7, 4

Guideline Recommendations

  • First-line recommendation: Guidelines specifically recommend beta-blockers for controlling ventricular rate in patients with AF complicating thyrotoxicosis 1
  • Non-selective preference: While guidelines don't always specify which beta-blocker to use, propranolol is the most widely studied non-selective beta-blocker for hyperthyroidism 1
  • Thyroid storm: For thyroid storm (severe hyperthyroidism), propranolol is particularly important and may require high doses 1

Dosing Considerations

  • Propranolol dosing: Initial daily doses of 160mg may need to be increased to 240-320mg for optimal effect in some patients 3
  • Metoprolol dosing: Even at higher doses (300-400mg daily), metoprolol has minimal effect on T3 conversion 3
  • Individualized dosing: Plasma levels of propranolol correlate with decreases in T3 and increases in rT3, suggesting that therapeutic failure may be due to suboptimal dosing 3

Special Considerations

  • Respiratory disease: In patients with bronchospastic disease, metoprolol may be preferred due to its relative beta-1 selectivity, though it should still be used cautiously 2
  • Thyroid storm: In severe hyperthyroidism or thyroid storm, propranolol's dual action (rate control and inhibition of T4 to T3 conversion) makes it particularly valuable 1
  • Discontinuation: Avoid abrupt withdrawal of either beta-blocker as this might precipitate a thyroid storm 2

Potential Adverse Effects

  • Bronchospasm risk: Propranolol poses a higher risk of bronchospasm due to its beta-2 blocking effects, while metoprolol has less effect on bronchial smooth muscle 2
  • Bradycardia: Both agents can cause bradycardia, heart block, and cardiac arrest, requiring careful monitoring 2
  • Masking symptoms: Both beta-blockers may mask certain clinical signs of hyperthyroidism (e.g., tachycardia) without affecting the underlying thyrotoxic process 2, 7

In conclusion, while both propranolol and metoprolol can control heart rate in hyperthyroidism with palpitations, propranolol offers additional benefits through inhibition of peripheral T4 to T3 conversion and better control of non-cardiac symptoms like tremor. For patients with contraindications to non-selective beta-blockers (such as severe bronchospastic disease), metoprolol remains a viable alternative 1, 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Effects and plasma levels of propranolol and metoprolol in hyperthyroid patients.

European journal of clinical pharmacology, 1980

Research

The assessment of β-adrenoceptor blocking drugs in hyperthyroidism.

British journal of clinical pharmacology, 1974

Research

Propranolol in the treatment of thyrotoxicosis: a review.

Postgraduate medical journal, 1976

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.